|
|
|
| Comparison of clinical effect and safety of Duloxetine and Escitalopram in the treatment of patients with depression |
| ZHANG Jin |
| Department of Somatic Diseases,Jinzhou Kangning Hospital,Liaoning Province,Jinzhou 121000,China |
|
|
|
|
Abstract Objective To compare the clinical effect and safety of Duloxetine and Escitalopram in the treatment of patients with depression,so as to provide reference for the treatment of psychiatric depression.Methods A total of 120 patients with depression admitted to the Department of Psychiatric of Jinzhou Kangning Hospital from February 2018 to February 2020 were selected as the research objects,and the patients were divided into the control group and the observation group by the random number table method,with 60 patients in each group.Patients in the control group were treated with Escitalopram,while patients in the observation group were treated with Duloxetine.The prognostic outcomes of the two groups were compared,including the total effective rate of treatment,the total incidence of adverse reactions and the depression score.Results The total effective rate of patients in the observation group was higher than that in the control group,and the difference was statistically significant (P＜0.05).The total incidence of adverse reactions in the observation group was lower than that in the control group,with statistically significant difference (P＜0.05).There was no significant difference in depression score between the two groups before treatment (P＞0.05).At 1,2,4,and 8 weeks after treatment,the depression scores of patients in the observation group were lower than those in the control group,with statistically significant differences (P＜0.05).Conclusion Both Duloxetine and Escitalopram can be used in the treatment of depression.However,compared with the treatment effect,safety and symptom improvement,Duloxetine has obvious advantages and is the preferred therapeutic drug.
|
|
|
|
|
|
| [1] |
刘文明，何宏，孙润珠，等.草酸艾司西酞普兰和盐酸度洛西汀治疗抑郁症对照研究[J].精神医学杂志，2016，29（1）：1-3.
|
| [2] |
黄飞，姜祥智，徐勇.量化治疗与常规治疗对抑郁症病人疗效及安全性比较[J].青岛大学医学院学报，2019，55（5）：548-551.
|
| [3] |
徐莹.艾司西酞普兰单用与联合度洛西汀治疗精神分裂症后抑郁的疗效及安全性的对照研究[J].实用临床医药杂志，2017，21（21）：15-18.
|
| [4] |
方昱，祝德秋，沈筱云.2015年上海市同济医院门诊抗抑郁药物的使用情况分析[J].现代药物与临床，2016，31（11）：1852-1855.
|
| [5] |
王丽，吴凡.浙江省11 家医院2013-2017年抗抑郁药使用分析[J].中国药房，2019，30（5）：134-137.
|
| [6] |
夏时炎，虞洪.度洛西汀对围绝经期及绝经后妇女抑郁症的疗效观察[J].现代妇产科进展，2014，（6）：503-504.
|
| [7] |
于淼，闫凤武，李丹.氟西汀与艾司西酞普兰对老年抑郁症外周血免疫T 淋巴细胞亚群的影响[J].中国医院药学杂志，2014，34（12）：1013-1017.
|
| [8] |
Mahajan SS，Tandon VR，Arora，et al.Comparative efficacy and safety of escitalopram ver sus desvenlafaxine in postmenopausal women with depression and anxiety：A randomized，open-label，comparative trial[J].J Midlife Health，2019，10（3）：141-146.
|
| [10] |
孟宪琦，王俊丽.奥氮平联合草酸艾司西酞普兰对抑郁症患者神经功能相关因子及细胞因子的影响[J].河北医学，2017，23（9）：1540-1543.
|
| [11] |
万姝.艾司西酞普兰对抑郁症患者各脑区5-HT DAINH NE 表达的影响研究[J].河北医学，2017，23（5）：712-716.
|
| [12] |
杨会增，李洁，高昕.奥氮平联合艾司西酞普兰对抑郁症患者的疗效及对神经功能与细胞因子的影响[J].中国慢性病预防与控制，2018，26（5）：375-377.
|
| [13] |
张德伦，陈林.阿戈美拉汀与艾司西酞普兰治疗抑郁症有效性与安全性的对照研究[J].中国医院药学杂志，2019，39（9）：966-968.
|
| [14] |
陈艳波，杨艳，张丽娜.米氮平联合艾司西酞普兰对抑郁症患者情绪、睡眠质量及认知功能的影响[J].中国医师杂志，2020，22（4）：580-583.
|
| [9] |
Kang SH，Kim BY，Kwon HI，et al.PLGA Microsphere Addition to 1-Hydroxy-2-napthoic Acid Enhances the Sustained Release of Escitalopram[J].Bull Korean Chem Soc，2019，40（8）：791-795.
|
| [15] |
王沛弟，陈丽君，刘刚，等.九味镇心颗粒联合度洛西汀治疗抑郁症的临床研究[J].现代药物与临床，2018，33（11）：93-96.
|
| [16] |
朱建峰，金卫东，孙峰俐.度洛西汀治疗抑郁症临床疗效及安全性国内研究的meta 分析[J].中华行为医学与脑科学杂志，2018，27（9）：858-864.
|
| [17] |
杜扬，邱昌建，李诗逸.度洛西汀与舍曲林治疗中国老年抑郁症患者的疗效与安全性的Meta分析[J].中国新药与临床杂志，2018，37（6）：351-357.
|
|
|
|
